Lip Cancer Risk Up for Some Solid Organ Transplant Recipients

This article originally appeared here.
Share this content:
Lip Cancer Risk Up for Some Solid Organ Transplant Recipients
Lip Cancer Risk Up for Some Solid Organ Transplant Recipients

TUESDAY, May 24, 2016 (HealthDay News) -- For solid organ transplant recipients, azathioprine dose and duration of immunosuppression are associated with increased risk of lip cancer, according to a study published in the June issue of the Journal of the American Academy of Dermatology.

Renhua Na, Ph.D., from the University of New South Wales in Sydney, and colleagues examined the correlation between the type, dose, and duration of iatrogenic immunosuppression and lip cancer. Data were included from a population-based cohort of all 4,141 adult liver, heart, and lung transplant recipients in Australia from 1984 to 2006. Longitudinal data were abstracted from medical records, and incident lip cancer (58 cases) and deaths (1,434 cases) were ascertained by linkage with national registries.

The researchers observed an increase in the risk of lip cancer with high mean daily dose of azathioprine (hazard ratio [HR], 2.28), longer immunosuppression duration (HR, 9.86), increasing year of age at transplantation (HR, 1.14), earlier era of transplantation (HR, 8.73), and smoking history (HR, 2.71).

"Higher doses of azathioprine increase lip cancer risk, with implications for managing immunosuppressed populations and our understanding of the relationship between solar ultraviolet radiation and lip cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »